BIO Asia–Taiwan 2023 亞洲生技大會

BIO Asia–Taiwan 2023 亞洲生技大會

講師

台康生技股份有限公司

 

Company Info

Name /EirGenix, Inc.

Address /No. 101, Lane 169, Kangning Street, Xizhi District, New Taipei City

Website /www.eirgenix.com

Presenter

Name /LEE-CHENG LIU

Title /Founder, President & CEO

Email /lcliu@eirgenix.com

Telephone /+886-2-7708-0123

Fax /+886-2-7708-1666

Mobile /

Company Type

Others:biopharmaceutical & CDMO service

About the Company

EirGenix is a contract development and manufacturing organization to provide high quality and cost-effectiveness service supporting our clients in development, analytical testing, and cGMP manufacturing of biopharmaceuticals from pre-clinical to commercial manufacturing. EirGenix has also been a leader in the development of HER2 breast cancer biosimilars. It has formed a licensing agreement with Sandoz to globally market. EirGenix offers the service and biologics to clients around the world.

Brief Description of main products or services

EirGenix offers contract services for biologics such as process development, analytical services and current Good Manufacturing Practice (cGMP) production in microbial and mammalian systems. It has helped clients with biological products from pre-clinical development to commercial manufacturing, including aiding in Taiwan’s first Covid-19 vaccine approved for emergency use.

EirGenix has also been a leader in the development of HER2 breast cancer biosimilars. We have formed a licensing agreement with Sandoz to globally market our trastuzumab biosimilar EG12014 It yielded positive results in global phase III clinical trials, and has been submitted to the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) for approval. EirGenix has several HER2 related breast cancer biosimilar in development,.

Contact Person

Name /Shao-Chi (Harry) Cheng

Email /sccheng@eirgenix.com

Phone /+886-2-7708-0123 #6802